CD4 and neoplasm: This is highlighted by a recent study where the addition of α-GalCer to nanoparticles encapsulating multiple tumour antigens and the TLR agonists CpG and MPLA improved the anti-tumour response in a mouse model by 5-fold and enhanced the frequency of NKT, NK and CD4+ T cells in the tumour microenvironment [98].